4. Discussion
single-vessel disease, bleeding, death, dyspnea, renal failure
RENAL FAILURE, DISEASE, COMPLICATIONS, BLEEDING
This randomized clinical trial compared clopidogrel and ticagrelor, two P2Y12 inhibitors, regarding their efficacy and side effects among patients who underwent elective PCI, with a follow-up period of six months. Our study showed that new-onset dyspnea was significantly more common among patients treated with ticagrelor rather than clopidogrel, though fewer MACEs occurred in the ticagrelor group.Storey et al. found that dyspnea among patients consuming ticagrelor was significantly more common than those using clopidogrel [When considering medication adherence, which means how actively patients are consuming their prescribed medications [Our study showed that MACEs were less common in the group taking ticagrelor, suggesting that ticagrelor may reduce the risk of MACEs more efficiently than clopidogrel. Xue et al. found no remarkable differences in benefiting from ticagrelor or clopidogrel use in patients who underwent PCI due to ACS in multiple-vessel disease. However, patients with single-vessel disease treated with ticagrelor had less adverse outcomes (such as MACE, hospitalization, and bleeding) than those taking clopidogrel [While we discovered no significant inequality between ticagrelor and clopidogrel regarding bleeding-related complications and noncardiac death, Misumida et al., in their meta-analysis and systemic review, reported that the risk of major bleeding among eastern Asian patients with previous ACS consuming ticagrelor was higher in comparison to the ones taking clopidogrel (OR: 1.52). They also reported that this difference could be attributed to the higher prevalence of renal failure and low BMI in the Asian population [